Skip Navigation



Annals of Oncology Advance Access published online on April 25, 2005
Annals of Oncology, doi:10.1093/annonc/mdi220
This Article
Right arrow Full Text (PDF)
Right arrow CME/CE:
Take the course for this article:
 Annals of Oncology course: part 2 iss...
Right arrow All Versions of this Article:
16/7/1100    most recent
mdi220v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haie-Meder, C.
Right arrow Articles by Guastalla, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haie-Meder, C.
Right arrow Articles by Guastalla, J. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received July 12, 2004
Revised February 17, 2005
Accepted February 17, 2005

Original article

SOR guidelines for concomitant chemoradiotherapy for patients with uterine cervical cancers: evidence update bulletin 2004

C. Haie-Meder 1, B. Fervers 2*, E. Fondrinier 3, M. Haugh 4, C. Lhomme 1, and J. P. Guastalla 4

1 Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), 75654 Paris Cedex 13, France; 2Institut Gustave Roussy, 94805 Villejuif Cedex, France;
2 Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), 75654 Paris Cedex 13, France; 3Centre Léon Bérard, 69373 Lyon Cedex 08, France;
3 Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), 75654 Paris Cedex 13, France; 4Centre Paul Papin, 49033 Angers Cedex 01, France
4 Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), 75654 Paris Cedex 13, France; 3Centre Léon Bérard, 69373 Lyon Cedex 08, France;

* To whom correspondence should be addressed.
B. Fervers, E-mail: fervers{at}lyon.fnclcc.fr


  Abstract

Background: In 1993 the French National Federation of Cancer Centres (FNCLCC) initiated the Standards, Options and Recommendations (SOR) project. This is a collaboration between the FNCLCC, the 20 French cancer centres, and specialists from French public universities, general hospitals and private clinics, and some specialists learned societies. The main objective is to develop clinical practice guidelines to improve the quality of health care and the outcome of cancer patients.

Materials and methods: The SORs are developed using a methodology based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.

Results: In 1999, the initial SORs for the management of women with cervical cancer were published. At that time the use of chemoradiotherapy was considered as an option. Since this original publication, five randomised trials comparing chemoradiotherapy with radiotherapy have been published, as well as a systematic review and two other clinical practice guidelines. In the light of this additional evidence, it was decided to update the guidelines on chemoradiotherapy in women with cervical cancer.

Conclusion: After selection, critical analysis and integration of new evidence, chemoradiotherapy has become a standard for women with cervical cancer.

Keywords: clinical practice guideline; concomitant chemoradiotherapy; uterine cervical cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.